Trial Information

A Prospective Study to Evaluate the Incidence of Skeletal Related Events In Prostate Cancer Patients Undergoing Androgen Deprivation Therapy (ADT).

A consequence of ADT is the gradual bone loss, so-called cancer treatment induced bone loss
(CTIBL). The current standard of care is the addition of Vitamin D and Calcium upon the
initiation of ADT. Moreover, bisphosphonates are now being considered to treat and prevent
CTIBL. However, bisphosphonates are costly, thus there is a desire to identify or target a
specific subset of patients who would most benefit from the treatment.

By obtaining baseline BMD and monitoring for Skeletal Related Events (SREs), we hope to
identify that specific sub-set of patients who would most benefit from the treatment. Using
a prospective, observational study design, we propose monitoring how physicians manage CTIBL
in their patients.